03576nam a22004095i 4500001001800000003000900018005001700027007001500044008004100059020001800100024003500118050001400153072001700167072002300184072001600207245019700223250001800420264006900438300006500507336002600572337002600598338003600624347002400660520207800684650001902762650003002781650002302811650001802834650001902852650003902871700007802910710003402988773002603022776003603048776003603084856004603120978-3-031-61992-2DE-He21320251030114645.0cr nn 008mamaa241228s2024    sz |    s    |||| 0|eng d  a97830316199227 a10.1007/978-3-031-61992-22doi 4aRC321-580 7aPSAN2bicssc 7aSCI0890002bisacsh 7aPSAN2thema10aModern CNS Drug Discoveryh[electronic resource] :bNovel Therapeutics for Psychiatric and Neurological Diseases: From Target Identification to Regulatory Approval /cedited by Rudy Schreiber.  a2nd ed. 2024. 1aCham :bSpringer Nature Switzerland :bImprint: Springer,c2024.  aXIX, 445 p. 80 illus., 63 illus. in color.bonline resource.  atextbtxt2rdacontent  acomputerbc2rdamedia  aonline resourcebcr2rdacarrier  atext filebPDF2rda  aThis new edition is a comprehensive guide to the intricate world of drug discovery and development. It provides readers with an update on basic and novel concepts, approaches and technologies that are used in the discovery and development of new therapeutics for diseases of the central nervous system (CNS). A major aim is to support the education of professionals and specialists in the biomedical neurosciences that will become the innovators, entrepreneurs, and leaders of the future. The educational focus is now enhanced by the inclusion of over 150 study questions available in the free Springer Nature Flashcard App, which makes this a unique book in its field. Divided into five sections, the book starts by introducing concepts and ideas to inspire the next generation of life scientists pursuing careers in drug discovery for CNS diseases. In the following section, key strategies and methods for identifying and testing novel drug targets are described. New chapters on important topics have been added, that is, the blood brain barrier, mass spectrometry, biased signaling and the exposome. The third section highlights strategies and technologies in translational CNS drug discovery and looks at safety and drug metabolism assessment, imaging techniques and functional testing to investigate drug treatment outcomes. The chapters in the fourth section address the emergence of transdiagnostic approaches as exemplified by the Research Domain Criteria initiative and non-invasive brain stimulation techniques. Finally, the book concludes with the late stages of drug development, such as the planning and performance of clinical trials, and regulatory approval. Written by experts from academia and industry, the book covers important fundamentals and best practices as well as current developments in neurotherapeutic research. It offers in-depth insights into the world of drug development and is essential reading for young scientists who are interested in translational research and want to prepare for an academic or industry career in CNS drug discovery. 0aNeurosciences. 0aPharmaceutical chemistry. 0aPharmacovigilance.14aNeuroscience.24aPharmaceutics.24aDrug Safety and Pharmacovigilance.1 aSchreiber, Rudy.eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt2 aSpringerLink (Online service)0 tSpringer Nature eBook08iPrinted edition:z978303161991508iPrinted edition:z978303161993940uhttps://doi.org/10.1007/978-3-031-61992-2